No Result
View All Result
  • Login
  • Register
Business & Technology
SUBSCRIBE
  • .
  • Thought Leadership
  • Conversations
  • International Voices
  • News
  • Wealth
  • Digital Transformation
  • Lifestyle
  • Videos
  • Podcasts
  • .
  • Thought Leadership
  • Conversations
  • International Voices
  • News
  • Wealth
  • Digital Transformation
  • Lifestyle
  • Videos
  • Podcasts
No Result
View All Result
Biztech Asia
Home News

An early Christmas present from Pfizer-BioNtech?

by editorial
19/11/20
in News
2 min read
0
An early Christmas present from Pfizer-BioNtech?

Drug makers Pfizer and BioNTech’s Covid-19 vaccine could secure emergency US and European authorisation next month after final trial results showed a 95% success rate with no serious side effects.

The US Food and Drug Administration (FDA) could grant emergency-use by the middle of December, and conditional approval in the European Union could be secured in the second half of December, BioNTech Chief Executive Ugur Sahin told Reuters TV.

The success rate of the vaccine developed by Pfizer-BioNTech was far higher than what regulators had said would have been acceptable. Experts said it was a significant achievement in the race to end the pandemic.

The vaccine’s effectiveness was found to be consistent across different ages and ethnicities. Out of the 170 volunteers who contracted the virus in Pfizer’s trial involving over 43,000 people, 162 had received a placebo and not the vaccine, meaning the vaccine was 95% effective. Of the 10 people who had severe Covid-19, one had received the vaccine.

According to Enrico Bucci, a biologist at Temple University in Philadelphia., it is a first in the history of mankind; less than a year from the sequence of the virus to the large-scale clinical trial of a vaccine, moreover based on a whole new technique.

The final trial analysis comes a week after initial results showed the vaccine was more than 90% effective. Moderna Inc also released preliminary data for its vaccine showing 94.5% effectiveness.

In a statement by US Health and Human Services Secretary Alex Azar, he said there are now two safe and highly effective vaccines that could be authorised by the Food and Drug Administration and ready to distribute within weeks.

The Moderna vaccine is likely to be authorised within 7-10 days of Pfizer receiving its EUA, US officials said, with states ready to begin distribution within 24 hours

The amazing results from the two vaccines, both developed with new messenger RNA (mRNA) technology, have raised hopes for an end to a pandemic that has killed more than 1.3 million people and ravaged global economies and ruined daily life.

It is a welcoming news as the virus is again running rampant around the world, setting records for new infections and hospitalisations almost daily.

Investors have treated vaccine development as a race between companies, although there is likely to be global demand for as much vaccine as can be produced for the foreseeable future.

Pfizer said it expects to make as many as 50 million vaccine doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.

According to Mike Ryan, the World Health Organization’s top emergency expert, it would be at least 4-6 months before significant levels of vaccination were taking place around the world.

Distribution of a Pfizer-BioNTech shot is more complex as it needs to store at ultra-cold temperatures of -70 degrees Celsius. It can, however, be kept in normal refrigeration for up to five days, or up to 15 days in a thermal shipping box.

Moderna’s vaccine can be stored for up to six months at -20 degrees Celsius though it is expected to be stable for 30 days at normal fridge temperatures of 2 to 8 degrees Celsius.

Of the dozens of drugmakers and research groups racing to develop the vaccines, the next late-stage data will likely be from AstraZeneca Plc with the University of Oxford in November or December. Johnson & Johnson said it is on track to deliver data this year.

Authorization of vaccines for children will take longer. Only Pfizer has started vaccinating volunteers under age 18 and as young as 12. Moderna and J&J have said they hope to start testing the vaccine in younger people soon.

Previous Post

Rakyat the true shareholders of digital transformation, not ‘tech giants’ or politicians

Next Post

Google’s move into consumer finance

editorial

editorial

Related Posts

Mizuho week ahead – Between an Ox & a Bull
News

Risky business

Mizuho Daily – Reflate & Roil and what to make of China’s 14th 5-Year Plan
News

Mizuho Daily – Reflate & Roil and what to make of China’s 14th 5-Year Plan

Business and technology quick bites
News

Business and technology quick bites

Business and technology quick bites
News

Business and technology quick bites

Dude, Where’s My Toys?
News

Dude, Where’s My Toys?

Equity and Oil market analysis: Stocks lower as bond market vigilantes return
News

Equity and Oil market analysis: Stocks lower as bond market vigilantes return

Next Post
Google’s move into consumer finance

Google's move into consumer finance

Institutional investors embrace cryptocurrencies

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

I agree to the Terms & Conditions and Privacy Policy.

Recommended Stories

NTT recognised at the Frost & Sullivan 2020 Asia Pacific Best Practices Awards

NTT recognised at the Frost & Sullivan 2020 Asia Pacific Best Practices Awards

Budget 2021 – Considerate, sufficiency yet to be seen

Budget 2021 – Considerate, sufficiency yet to be seen

Mizuho Week Ahead – Silver Linings (& Squeeze)?

Mizuho Week Ahead – Silver Linings (& Squeeze)?

Popular Stories

  • Economic recovery: an elusive thought?

    Economic recovery: an elusive thought?

    0 shares
    Share 0 Tweet 0
  • Cannibalising your business can be profitable

    0 shares
    Share 0 Tweet 0
  • Sexual fulfillment builds confidence and well-being

    0 shares
    Share 0 Tweet 0
  • Tech Stocks – Ant gets stomped on but REITS offer stability amid volatility

    0 shares
    Share 0 Tweet 0
  • Singapore REITS and China tech stocks – Which should you buy?

    0 shares
    Share 0 Tweet 0

About Us

A Business and Technology digital publication that engages business leaders in business and technology conversations to help everyone pivot, adapt, and thrive in these turbulent times.

LEARN MORE »

Contact Us

Phone: 016-2011 050

Email: editor@biztech.asia

Address:
Level 18, Boutique Office 1 (B01-C)
Menara 2, No. 3, Jalan Bangsar,
KL Eco City, 59200, Kuala Lumpur.

Email Newsletter

Loading

© 2020 Business & Technology - made possible by Milestones Digital.

No Result
View All Result
  • Home
  • Thought Leadership
  • Conversations
  • International Voices
  • News
  • Wealth
  • Digital Transformation
  • Lifestyle
  • Videos
  • Podcasts
  • Login
  • Sign Up

© 2020 Business & Technology - made possible by Milestones Digital.

Welcome Back!

Sign In with Facebook
Sign In with Google
OR

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Sign Up with Facebook
Sign Up with Google
OR

Fill the forms bellow to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.
All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

will use the information you provide on this form to be in touch with you and to provide updates and marketing.